Ultragenyx Pharmaceutical(US:RARE) TMX Newsfile·2026-03-10 16:24Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of misleading statements regarding the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta, which led to significant stock price declines following study failures [2][4][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements about the Phase III Orbit study's results and the reliability of the data [4]. - It is claimed that Ultragenyx created a false impression of confidence in the study's outcomes while downplaying the risks associated with the data [4]. - The company failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived efficacy of the treatment [4]. Group 3: Stock Price Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance, resulting in a stock price drop of over 25% [5]. - Following the December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].